Nektar Therapeutics Inc (NKTR)

17.10
0.57 3.20
NASDAQ : Health Care
Prev Close 17.67
Open 17.59
Day Low/High 16.93 / 17.66
52 Wk Low/High 9.16 / 17.55
Volume 758.48K
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 136.73M
Market Cap 2.37B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum

Rev's Forum: Let's See If Bulls Can Sustain Friday's Momentum

The big issue is if the market can build on Friday's jobs good news.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Using My Metal Detector Amid Gold and Silver Strength

Using My Metal Detector Amid Gold and Silver Strength

Computer programming has found that buying bad-news dips is a consistent winner.

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate

Nektar Therapeutics Announces Executive Management Promotions

Nektar Therapeutics Announces Executive Management Promotions

John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar

Nektar Therapeutics (NKTR) Weak On High Volume Today

Nektar Therapeutics (NKTR) Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Novice Trade: Nektar Therapeutics

Plus an update on the Urban Outfitters trade from yesterday.

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) stock is declining on Wednesday afternoon despite posting better-than-expected 2015 fourth quarter results after yesterday’s closing bell.

Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings

Baxalta Announces Submission Of Supplemental BLAs To Expand Use Of ADYNOVATE To Pediatric Patients And Surgical Settings

- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], currently FDA-approved for adolescent and adult hemophilia A patients 12 years and older, offers proven prophylaxis with a simple, twice-weekly dosing schedule

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

General Motors, MetLife and Tesla: Doug Kass' Views

General Motors, MetLife and Tesla: Doug Kass' Views

Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.

Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research

Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research

New Paper Documents Durable Anti-Tumor Efficacy, Safety and Immune Mechanism of Action of NKTR-214 in Multiple Tumor Models as well as a Favorable Safety Profile in Non-Human Primates (NHPs)

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

- Topline results find no inhibitors to ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], treatment were reported and nearly 73 percent of treated patients experienced zero joint bleeds

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase...